Join

Compare · NVS vs TYRA

NVS vs TYRA

Side-by-side comparison of Novartis AG (NVS) and Tyra Biosciences Inc. (TYRA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVS and TYRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $262.75B, about 164.7x TYRA ($1.60B).
  • Over the past year, NVS is up 7.3% and TYRA is up 82.0% - TYRA leads by 74.8 points.
  • NVS has been more active in the news (5 items in the past 4 weeks vs 4 for TYRA).
  • NVS has more recent analyst coverage (25 ratings vs 21 for TYRA).
PerformanceNVS+7.27%TYRA+82.03%
2025-09-09+0.00%2026-09-09
MetricNVSTYRA
Company
Novartis AG
Tyra Biosciences Inc.
Price
$137.45-0.16%
$21.61-19.15%
Market cap
$262.75B
$1.60B
1M return
-12.34%
-17.83%
1Y return
+7.27%
+82.03%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
5
4
Recent ratings
25
21
NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

TYRA

Tyra Biosciences Inc.

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Latest NVS

Latest TYRA